tetano
Editor, Senior Moderator
J Infect Chemother
. 2022 Apr 7;S1341-321X(22)00108-8.
doi: 10.1016/j.jiac.2022.03.029. Online ahead of print.
REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan
Ayana Sakurai[SUP] 1 [/SUP], Shoko Marshall[SUP] 2 [/SUP], Tomoko Ogasawara[SUP] 1 [/SUP], Toshie Ogasawara[SUP] 1 [/SUP], Yoshikazu Aoka[SUP] 3 [/SUP], Hiroshi Sakura[SUP] 1 [/SUP], Yasuko Uchigata[SUP] 4 [/SUP], Tetsuya Ogawa[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: A new treatment for coronavirus disease (COVID-19), REGN-COV2, a cocktail consisting of two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been approved for patients at a risk of developing more severe disease.
Methods: We retrospectively reviewed patients recently diagnosed with COVID-19 with risk factors for severe infection, who were treated with the REGN-COV2 antibody cocktail between July and September 2021. The REGN-COV2 antibody cocktail was administered to patients within 7 days of disease onset, with an oxygen saturation of >93%, and with at least one comorbidity. We investigated the percentage of patients with COVID-19-related hospitalization or death, the duration of symptoms after treatment, and the adverse effects of treatment.
Results: A total of 108 patients were reviewed. Of them, 64% were aged ≥50 years, 31% had obesity, 36% had hypertension, and 18% had diabetes. In addition, 49% had multiple risk factors for severe COVID-19. Overall, 12 patients (11%) needed COVID-19-related hospitalization. No adverse effects of treatment were observed.
Conclusions: This study shows that treatment with the REGN-COV2 antibody cocktail is safe and beneficial in patients at a risk of developing severe COVID-19.
Keywords: Casirivimab; Imdevimab; Neutralizing monoclonal antibodies; SARS-CoV-2.
. 2022 Apr 7;S1341-321X(22)00108-8.
doi: 10.1016/j.jiac.2022.03.029. Online ahead of print.
REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan
Ayana Sakurai[SUP] 1 [/SUP], Shoko Marshall[SUP] 2 [/SUP], Tomoko Ogasawara[SUP] 1 [/SUP], Toshie Ogasawara[SUP] 1 [/SUP], Yoshikazu Aoka[SUP] 3 [/SUP], Hiroshi Sakura[SUP] 1 [/SUP], Yasuko Uchigata[SUP] 4 [/SUP], Tetsuya Ogawa[SUP] 1 [/SUP]
Affiliations
- PMID: 35414436
- DOI: 10.1016/j.jiac.2022.03.029
Abstract
Introduction: A new treatment for coronavirus disease (COVID-19), REGN-COV2, a cocktail consisting of two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been approved for patients at a risk of developing more severe disease.
Methods: We retrospectively reviewed patients recently diagnosed with COVID-19 with risk factors for severe infection, who were treated with the REGN-COV2 antibody cocktail between July and September 2021. The REGN-COV2 antibody cocktail was administered to patients within 7 days of disease onset, with an oxygen saturation of >93%, and with at least one comorbidity. We investigated the percentage of patients with COVID-19-related hospitalization or death, the duration of symptoms after treatment, and the adverse effects of treatment.
Results: A total of 108 patients were reviewed. Of them, 64% were aged ≥50 years, 31% had obesity, 36% had hypertension, and 18% had diabetes. In addition, 49% had multiple risk factors for severe COVID-19. Overall, 12 patients (11%) needed COVID-19-related hospitalization. No adverse effects of treatment were observed.
Conclusions: This study shows that treatment with the REGN-COV2 antibody cocktail is safe and beneficial in patients at a risk of developing severe COVID-19.
Keywords: Casirivimab; Imdevimab; Neutralizing monoclonal antibodies; SARS-CoV-2.